An open-labeled, randomized, single dose, three period, 2-sequence crossover study to investigate the pharmacokinetics of darifenacin when given as 7.5 mg oral doses of a modified release suspension, as compared to the commercial modified release tablet in healthy adult

Trial Profile

An open-labeled, randomized, single dose, three period, 2-sequence crossover study to investigate the pharmacokinetics of darifenacin when given as 7.5 mg oral doses of a modified release suspension, as compared to the commercial modified release tablet in healthy adult

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Oct 2007

At a glance

  • Drugs Darifenacin (Primary)
  • Indications Overactive bladder
  • Focus Pharmacokinetics
  • Sponsors Novartis
  • Most Recent Events

    • 11 Oct 2007 Procter and Gamble reported as trial sponsor.
    • 11 Jan 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top